Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 94

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 94
---
 comparison
between conventional small-molecule drugs and their nanoparticle/liposomal equivalents. For example, conventional Amphotericin B averages
approximately $51 per 50 mg dose (source: Drugs.com price guide), whereas liposomal Amphotericin B (AmBisome®) averages approximately
$341 per dose, reflecting a ~7x premium (Lee et al., Lancet Global Health, Sept 2024, “Paving the way for affordable and
equitable liposomal amphotericin B access worldwide”).

For Liposomal Nano-Mupirocin, we benchmarked against:

| - | Ceftriaxone: the current recommended                                                       
 treatment for uncomplicated gonorrhea (including resistant strains) as recommended by CDC. 
 Average price per treatment course is $538 [5]                                             |

| - | Topical Mupirocin (~$45 per 50g). [6] |

| - | Based on these benchmarks and the ~7x                                                               
 premium commonly observed for liposomal formulations, we estimate a potential treatment course      
 price of $315–$1,200, depending on market segment, with an illustrative base case of                
 $600. The lower end of this range corresponds to assumptions of low-income or no-profit procurement 
 pricing, while the upper end reflects premium pricing in private market segment.                    |

These ranges are assumptions only.
Nano-Mupirocin is still in preclinical development and has not been approved by any regulatory authority. We do not yet know the final
dosage, or number of injections required per treatment course, and actual pricing will depend on multiple factors including clinical
results, regulatory approval, reimbursement, adoption, and competition.

Epidemiology and Estimated Market Opportunity for Resistant Gonorrhea Indication

According to the CDC’s 2022 STD Surveillance
Report, the U.S. reports approximately 710,000 gonorrhea cases annually, with Ceftriaxone resistance emerging in approximately 5% of cases
[7], resulting in ~91,000 Ceftriaxone-resistant infections per year.

Total Addressable Market (TAM) for Ceftriaxone-Resistant Gonorrhea

The TAM represents the entire pool of patients who suffer from
the condition, have been diagnosed, and could theoretically benefit from our therapy.

U.S. Case

| - | Annual gonorrhea cases: ~710,000 |

| - | Ceftriaxone resistance prevalence: